Related Experiment Video
Updated: Jul 25, 2026
08:25
Contact Hypersensitivity as a Murine Model of Allergic Contact Dermatitis
Published on: September 26, 2022
Interleukin-1 receptor antagonist suppresses contact hypersensitivity
S Kondo1, S Pastore, H Fujisawa
1Division of Dermatology, Sunnybrook Health Science Centre, University of Toronto, Canada.
The Journal of Investigative Dermatology
|September 1, 1995
Summary
Interleukin-1 receptor antagonist (IL-1ra) effectively inhibits contact hypersensitivity (CHS) in mice by blocking interleukin-1 (IL-1) signaling. This blockade reduces inflammation during both sensitization and elicitation phases of CHS.
Area of Science:
- Immunology
- Dermatology
Background:
- Interleukin-1 (IL-1) is implicated in contact hypersensitivity (CHS), but its precise role is debated.
- Interleukin-1 receptor antagonist (IL-1ra) neutralizes IL-1 activity without agonistic effects.
Purpose of the Study:
- To investigate the role of IL-1 in CHS by examining the effects of IL-1 receptor blockade using IL-1ra.
- To evaluate the efficacy of exogenous IL-1ra in modulating CHS responses in a murine model.
Main Methods:
- In vivo study using a murine model of contact hypersensitivity (CHS).
- Local administration of recombinant human IL-1ra to BALB/c mice before or after dinitrofluorobenzene challenge.
- Assessment of CHS by measuring ear swelling and inflammatory cell infiltration.
- Dose-response analysis of IL-1ra efficacy.
- Evaluation of IL-1ra effects on phenol-induced inflammation.
Main Results:
- Local IL-1ra injection significantly reduced CHS ear swelling (36%–43%) in a dose-dependent manner.
- IL-1ra administration decreased inflammatory cell infiltration and dermal edema.
- Suppression of CHS was observed when IL-1ra was administered within 24 hours before challenge or before sensitization.
- IL-1ra did not inhibit phenol-induced inflammation, indicating specificity.
Conclusions:
- IL-1ra effectively inhibits both sensitization and elicitation phases of CHS in mice.
- These findings highlight IL-1's role as an immune potentiator in CHS.
- IL-1ra demonstrates therapeutic potential for managing CHS-related inflammation.
Related Concept Videos
01:27Allergic Drug Reactions
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:30Hypersensitivities
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
01:30Drug Toxicity: Allergic Reactions
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
01:29Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...